Short answer
Dexcom (DXCM) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $1.2B (up 21.6% year over year) with net income of $284M.
Q3 2025 key financials · XBRL
- Revenue
- $1.2B
- +21.6% YoY · +4.5% QoQ
- Net income
- $284M
- +110.8% YoY · +57.8% QoQ
- Operating margin
- 20.1%
- Gross margin
- 60.5%
- EPS (diluted)
- $0.71
- +115.2% YoY · +61.4% QoQ
Source: XBRL data from the Dexcom (DXCM) Q3 2025 10-Q on SEC EDGAR. USD.
Dexcom Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.21B in Q3 2025, up 22% YoY from $994.2M in Q3 2024
- Operating margin 20.0% vs 15.3% YoY; net income margin 23.5% vs 13.5% YoY; net income $283.8M up 111% YoY
- Best segment: US revenue $851.9M up 21% YoY; worst: Reusable Hardware revenue down to 3% of total revenue from 4% YoY
- Cash, cash equivalents, and short-term securities $3.32B at quarter-end; operating cash flow $659.9M, up 231% YoY
- Near-term outlook: management highlights continued customer growth, pricing headwinds, and expects cash from operations sufficient for core business funding
Risk Factors
- No newly added risk factors this quarter; risk section supplements and supersedes 2024 10-K disclosures
- No material changes to previously disclosed risk factors; risks remain consistent with 2024 10-K filing
- Ongoing regulatory risk related to product approvals and compliance impacting market access and launch timing
- Operational risk around supply chain disruptions affecting near-term production and delivery schedules
- Financial risk includes currency exposure from international sales impacting revenue translation and margins
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dexcom quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.